http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2681214-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
filingDate | 2012-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f159f23260a4cb3774363aea583b37b2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd53ce2c4146d033830f604a531158d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de6be8cc84d79459d55ea96bb08b929e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b5ce6af00899c64f688384b241ad700 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fc1b58f4f9603395c75ae2c2c2b0c2e |
publicationDate | 2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2681214-A1 |
titleOfInvention | Bridged piperidine derivatives |
abstract | The present invention relates to compounds of formula (l); hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N; hetaryl II is a six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, or N, wherein at least one ring is aromatic in nature; R 1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen or halogen; R 2 is lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, cycloalkyl substituted by lower alkyl or lower alkyl substituted by halogen, or is lower alkyl substituted by hydroxy, or is furyl, or is O-benzyl, (CH2)p-phenyl, optionally substituted by halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkyl or by cyano; R 3 is hydrogen or lower alkyl; Y is (CH 2 )n-, -CH 2 OCH 2 -, -CH 2 O-, CH 2 S-, -CH 2 SCH 2 - and is bonded to two of the ring carbon atoms, bonding being to either the ring carbon atoms a and b or the ring carbon atoms c and d; p is 0 or 1; m is 0, 1 or 2; if m is 2 then R 1 may be the same or different; -75- n is 2 or 3; o is 0, 1 or 2, if o is 2, then R 2 may be the same or different; or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimers disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome. |
priorityDate | 2011-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 473.